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Enriched environment reduces glioma growth
through immune and non-immune mechanisms
in mice
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Alessandro Rosa3, Alessandra Porzia4, Fabrizio Mainiero5, Vincenzo Esposito6,7, Clotilde Lauro1,
Giorgia Benigni4, Giovanni Bernardini4, Angela Santoni4,6 & Cristina Limatola1,6
Mice exposed to standard (SE) or enriched environment (EE) were transplanted with murine
or human glioma cells and differences in tumour development were evaluated. We report that
EE exposure affects: (i) tumour size, increasing mice survival; (ii) glioma establishment,
proliferation and invasion; (iii) microglia/macrophage (M/Mf) activation; (iv) natural killer
(NK) cell infiltration and activation; and (v) cerebral levels of IL-15 and BDNF. Direct infusion
of IL-15 or BDNF in the brain of mice transplanted with glioma significantly reduces tumour
growth. We demonstrate that brain infusion of IL-15 increases the frequency of NK cell
infiltrating the tumour and that NK cell depletion reduces the efficacy of EE and IL-15 on
tumour size and of EE on mice survival. BDNF infusion reduces M/Mf infiltration and CD68
immunoreactivity in tumour mass and reduces glioma migration inhibiting the small G protein
RhoA through the truncated TrkB.T1 receptor. These results suggest alternative approaches
for glioma treatment.
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E
xposure to an enriched environment (EE), obtained with
prolonged physical, social and sensory stimulation, has been
described as beneficial for better recovery from several
neuropathologies such as stroke, Parkinson’s disease, epilepsy and
Alzheimer’s disease1. In animal models, EE exposure increases
hippocampal neurogenesis, improves performances in several
memory tests, induces anatomical and functional changes in
synaptic connections, increasing dendrite spine density and
potentiating long-term synaptic transmission and modulates
cytokine and growth factor levels both centrally, in the cerebral
liquor and peripherally, in the plasma2,3.
Less clear is the effect of EE on cancer, despite the relevance
of the issue. Significant reduction of growth, incidence and
proliferation of subcutaneous implanted melanoma and colon
cancer is reported on EE housing, with involvement of
hypothalamic brain-derived growth factor (BDNF), sympathetic
innervation of white fat and inhibition of leptin levels4. However,
less unambiguous is the effect of EE on B-cell lymphoma or breast
cancer, and discordant results on the effect on tumour growth in
mice housed in EE compared with those housed in standard
environment (SE) are reported from different laboratories,
with possible variations because of differences in experimental
conditions and other unchecked parameters, such as
microbiota5–7. Of note, EE has important effects on
immunological parameters, as well as on the activation of
immune effector cells that play relevant roles in the control of
transformed cells, including natural killer (NK) cells8.
Here we investigated for the first time the effect of EE on
progression and development of glioma in mice. We choose
malignant glioma as it is the most diffuse and aggressive
neoplasm of the nervous system, characterized by high invasive-
ness and proliferation, diffuse apoptosis and/or necrosis, astro-
gliosis and microglia/macrophage (M/Mf) activation, with a
poor prognosis. To this aim, we transplanted murine glioma
(GL261) into the brain of mice housed in EE or in SE. Results
show that EE exposure reduces tumour size and proliferation rate
of glioma cells, with increased survival. Similar results on tumour
size are also obtained with the human U87MG and with the stem-
like CD133þ GL261 glioma cells. Interleukin-15 (IL-15) and
BDNF are two key mediators of these effects, since they increase
in the brain of EE mice, and their in situ administration reduces
tumour size in glioma-bearing mice, similarly to EE. We describe
that IL-15 increases NK1.1þ and CD69þ cell infiltration in
tumour area and that NK cell depletion reduces the efficacy of
IL-15 administration on tumour growth and of EE on tumour
growth and mice survival. BDNF has direct effects on tumour
cells, reducing glioma cell migration in vitro and impairing the
expression of the phagocytic marker CD68 on M/Mf, and their
infiltration in the tumour mass. These novel results encourage
clinical trials testing the effect of EE, IL-15 and BDNF in humans
suffering from malignant glioma.
Results
Enriched environment affects glioma growth and mice survival.
At weaning (21 day old), C57BL/6 mice were housed for 5 weeks
in SE or EE, as described in Methods (Supplementary Fig. 1a).
As control of EE efficacy, the effect on hippocampal synaptic
plasticity was tested9: mice housed in EE (hereafter EE mice) have
a robust increase in long-term potentiation (LTP) expression,
versus SE mice, as measured by field excitatory postsynaptic
potential (fEPSP) recordings in the CA1 region (Supplementary
Fig. 1b; LTP evoked by 100Hz train). EE mice also have a 7%
reduction of body weight compared with SE mice (Supplementary
Fig. 1c), likely because of the increased physical activity.
After this period, C57BL/6 mice were brain-transplanted
with syngeneic GL261 glioma cells (7.5 105 cells) in the right
striatum, left in their original cages and analysed at different
times for tumour volume. Figure 1a shows that 11 days after
glioma transplantation, the brains of EE mice have smaller
tumours and the difference is maintained at 17 days with a
reduction in tumour volume to 23.9±6% of SE. Tumour size
(from now on analysed on 17 days) was also evaluated with the
brain-clearing technique and ultramicroscopy (using tag Red
Fluorescent Protein (RFP) GL261, see Methods), confirming an
unambiguous reduction in the brain of EE mice (Fig. 1b and
Supplementary Movies 1–4). The reduction in tumour size was
also observed with different glioma cells, namely the human
U87MG and the stem-like CD133þ murine GL261 cells (Fig. 1c).
Enriched housing significantly has an impact on the survival
time of glioma-bearing mice (Fig. 1d): SE mice have a mean
survival time of 22.6±1.6 days that increases to 65.8±15.2 days
in EE mice. Interestingly, EE mice also have an increased
resistance to develop the injected tumour: in SE, 2/55 injected
mice (3.5%) do not develop the transplanted tumour, while in EE
mice this value raises to 13/49 (26.5%, Fig. 1e).
Additional experiments were performed to evaluate the time
dependency of EE exposure. With this aim, mice were exposed to
EE for 1, 3 or 5 weeks before tumour transplantation, and
analysed as above, after 17 days. Results shown in Fig. 1f
demonstrate that 1 week is ineffective, while 3 weeks of EE
exposure are sufficient to obtain significant reduction in glioma
size, suggesting a possible ‘dose-dependent’ effect. We also
investigated whether the age of mice at the beginning of the EE
protocol could influence the effects on glioma growth. For this
reason 2-month-old mice (adult) were housed in EE or SE and
transplanted with GL261 as described. Data reported in Fig. 1g
demonstrate that exposure to EE has similar effects on adult in
comparison with weaned mice (Fig. 1a), thus excluding an age-
dependent effect, at least for the periods taken into account. We
also evaluated whether exposure to EE simultaneously to glioma
transplantation could be efficient in contrasting the tumour
growth: results reported in Fig. 1h indicate, after 17 days, a non-
significant tendency to reduction between this group of mice
(post-EE) and those housed in SE, in contrast to EE mice
(**Po0.01, Student’s t-test, post-EE versus EE group). These data
indicate that the effect of EE housing is significant when the brain
is conditioned before tumour implantation and likely requires
longer periods to become effective.
The brains of SE or EE mice were compared for cell
proliferation in tumour mass (as 5-bromo-20-deoxyuridine
(BrdU) incorporation), astrocyte activation at the tumour border
(glial fibrillary acidic protein, GFAPþ ), M/Mf infiltration (F4/
80þ ) and activation of phagocytic activity (CD68þ ) within the
tumour. Data shown in Fig. 2a show that EE affects cell
proliferation, reducing the extent of BrdUþ cells in tumour mass.
Astrogliosis is also reduced by EE (Fig. 2b), while M/Mf
infiltration is not affected (Fig. 2c). In contrast, CD68þ cells are
significantly reduced in EE in comparison with SE and are only
detected in the tumour region, and not in healthy parenchyma
(Fig. 2d). CD68 staining is confined to M/Mf population (as
verified by co-labelling with GFPþ cells in CX3CR1þ /GFP mice,
Supplementary Fig. 2), being completely absent in glioma cells.
Cerebral slices were also analysed for glioma cell invasiveness
towards the healthy brain parenchyma in SE and EE conditions.
We observe that EE mice have a reduced number of glioma cells
protruding more than 150 mm from the main tumour mass
(Fig. 2e), indicative of a reduced tendency to migrate and invade
the surrounding tissue.
Enriched environment changes the glioma microenvironment.
In order to identify the factors responsible for the beneficial
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effects of EE in the brain of glioma-bearing mice, real-time–PCR
(RT–PCR) analyses were performed on cerebral hemispheres of
SE and EE mice, on sham insult or glioma transplantation. On EE
exposure, a significant increase in BDNF is observed in both the
hemispheres of sham-operated (Supplementary Table 1; Po0.05,
Student’s t-test, n¼ 3) and glioma-bearing mice (Table 1;
Po0.01, Student’s t-test, n¼ 4). Comparable results are obtained
measuring BDNF protein levels using enzyme-linked immuno-
sorbent assay (ELISA; see Supplementary Fig. 3). Differently,
IL-15 mRNA levels increase, on EE, in both brain hemispheres of
tumour-bearing mice (Table 1), not increasing in sham-operated
mice (Supplementary Table 1). Other chemokines and cytokines
known to be involved in glioma progression, such as CCL2,
CXCL10 and IL-6, are selectively upregulated in the glioma-
bearing hemisphere, and these increases are strongly reduced in
EE mice (Table 1).
We then attempted to identify the source of IL-15 and BDNF
produced in the brain of EE mice, and we focused on CD11bþ
cells, mainly comprising microglia, macrophages, NK and
dendritic cells. To this aim, highly purified (490%) CD11bþ
cells were isolated from the brain of SE and EE glioma-bearing
mice and analysed for cytokine expression (using RT–PCR).
Data shown in Table 2 indicate that, in EE mice, IL-15 increase is
restricted to CD11bþ cells, while similar increase in BDNF levels
is observed in CD11bþ and CD11b cells.
IL-15 promotes NK cell accumulation in the tumour site. We
focused our attention on the role played by IL-15 in the brain of
EE glioma-bearing mice. Since it is known that IL-15 regulates
NK cell proliferation/maturation and effector functions, we
wondered whether EE resulted in an increased number and
activation state of NK cell-infiltrating brain parenchyma.
Preliminarily, we analysed the brain of SE and EE mice for
leukocyte infiltration and activation by the expression, respec-
tively, of CD45þ and CD69þ markers and data shown in
Fig. 3a,b indicate that these cells, confined in the tumour area,
increase in EE. Sham-injected mice have no brain-infiltrating
CD45þ cells, independently of housing conditions (0.14±0.06%
of total, n¼ 6). Similar evidence of cell infiltration was obtained
using haematoxylin/eosin staining (Supplementary Fig. 4a).
Brains of EE mice also have a significant increase in NK1.1þ
cells, as evidenced by staining slices with anti-NK1.1 monoclonal
antibody, that recognizes an epitope of the NKR1Pc-activating
receptor (Fig. 3c). Leukocytes were also isolated from the brain by
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Figure 1 | Exposure to EE reduces glioma growth and prolongs survival. (a) The mean tumour volumes at 11 and 17 days after implantation of glioma cells
into the striatum of C57BL/6 mice, housed in SE or EE, as indicated, from at least 11 mice per conditions. *Po0.05, **Po0.01, Student’s t-test.
Representative coronal brain sections are shown on the right for each condition at 17 days. Scale bar, 1mm. (b) Quantification of tumour volumes under the
same experimental conditions as in a, at 17 days, with the brain-clearing technique (n¼ 7–8; **Po0.001 Student’s t-test). Representative Movies are
shown as Supplementary Material.(c) The mean tumour volumes (±s.e.m.) at 17 days after implantation of GL261, purified CD133þ GL261 or U87MG
glioma cells into the striatum of C57BL/6, or SCID mice housed in SE or EE, as indicated; seven animals per condition. **Po0.01, Student’s t-test.
(d) Kaplan–Meier survival curves of SE (red) and EE (blue) GL261 glioma-bearing mice (n¼ 5 per group; log-rank test **Po0.01). (e) Tumour resistance in
SE and EE mice expressed as total number of mice with (black) and without (grey) brain tumour 17 days after GL261 transplantation.
(f) ‘Dose dependency’ of EE exposure on tumour volume (n¼ 7 per group; *Po0.05; **Po0.01, one-way ANOVA. (g) Effect of SE or EE housing on
2-month-old mice transplanted with glioma (n¼ 5 per group; *Po0.05, Student’s t-test). (h) Effect of housing in SE and EE before (EE, for 5 weeks) or after
tumour transplantation (post-EE, for 17 days) on tumour volume (all mice analysed 17 days after tumour transplantation). Data are from at least five mice
per group. **Po0.01, Student’s t-test.
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Percoll gradient and analysed using immunofluorescence and
fluorescence-activated cell sorting (FACS): data shown in Fig. 3d
confirm, among the infiltrated leukocytes, an increased frequency
of NK cells (specifically in the ipsilateral hemisphere, evidenced as
NK1.1þ /CD3 /CD45þ ) in EE versus SE mice. No significant
differences in NKT cell (NK1.1þ /CD3þ /CD45þ ) frequency is
observed in the brain of SE and EE mice (SE: 0.22±0.07%; EE:
0.38±0.03%). Interestingly, NK1.1/CD3/CD69 co-staining
demonstrates that the CD69þ cell population modulated by EE is
mainly composed of NK cells (Fig. 3e), being CD69 not increased
in T-cell population (NK1.1 /CD3þ /CD69þ cells, SE:
7.65±2.59%; EE: 9.20±2.01%, n¼ 6). NK cell population also
has increased CD69 mean fluorescence intensity on EE (Fig. 3f),
indicating increased activation state. The functional state of these
cells is also confirmed by granzyme B (9.76±3.2%) and inter-
feron (IFN)-g (5.19±1.7%) expression (n¼ 6). All together, these
data demonstrate an increase in activated antitumour effector
cells in the brain of EE mice. Higher frequency of NK cells is also
observed in the blood of EE mice, with an increased capacity to
produce IFN-g in response to cytokine stimulation (Supplemen-
tary Fig. 4b). Accordingly, in the brain of EE mice we observe the
increased expression of another NK cell activating cytokine, IL-2,
with no variation in IL-18, IL-12p35 or IL-12p40 (Supplementary
Table 2).
To further analyse the role played by NK cells, we decided to
selectively deplete them in glioma-bearing mice by repeated
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Figure 2 | EE modulates tumour microenvironment. (a) The mean (±s.e.m.) area of BrdUþ cells in tumour area (as % of the tumour area) at 17 days
after tagRFP-GL261 implantation in mice housed in SE or EE, as indicated (*Po0.05; Student’s t-test; n¼4 mice per condition). Representative
immunofluorescence of proliferating BrdUþ cells (green) under the two experimental conditions are shown on the right. Red: tagRFP-GL261 cells.
(b) The mean (±s.e.m.) area of GFAPþ cells (as % of the tumour area, *Po0.05, Student’s t-test, n¼4 mice per condition) 17 days after tagRFP-GL261
transplantation in mice housed in SE or EE, as indicated. Representative immunofluorescences of astrogliosis, seen as GFAPþ cells (green) are shown on
the right for the two experimental conditions. Red: tagRFP-GL261 cells. (c,d) The mean (±s.e.m.) area of F4/80þ (c) and CD68þ (d) cells (as %
of the tumour area, n¼ 3–4 mice per condition) 17 days after GL261 transplantation in mice housed in SE or EE, as indicated. Right: representative
immunofluorescences of M/Mf glioma infiltration (c, F4/80 in red) and activation (d, CD68 in green, *Po0.05 Student’s t-test) 17 days after GL261
transplantation. Nuclei are evidenced with Hoechst (blu). (e) The mean number (±s.e.m.) of glioma cells invading the brain parenchyma for more than
150mm beyond tumour border 17 days after glioma cell transplantation in SE or EE (n¼4 mice per condition; *Po0.05 Student’s t-test). Right:
representative coronal brain sections stained with haematoxylin/eosin. Black arrows indicate glioma cells invading the brain parenchyma beyond the
main tumour border (dashed line) for more than 150mm. For all the panels: scale bars, 10 mm.
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injections of anti-NK1.1 Ab (performed at  2, 0,þ 2 and þ 7
days from glioma injection). The evaluation of the frequency of
NK cells (CD3 /NK1.1þ ) at þ 7 and þ 17 days in the
peripheral blood confirms successful NK cell depletion in both
SE and EE mice (Supplementary Fig. 4c). NK cell-depleted mice
always have larger tumours, in comparison with non-depleted
ones (Fig. 3g), demonstrating that glioma is susceptible to the
antitumour activity of NK cells. Interestingly, the effects of EE on
tumour size are strongly reduced but not abolished in NK
cell-depleted mice (47% reduction) in comparison with normal
mice (75% reduction; Po0.05, two-way analysis of variance
(ANOVA)). The effect of NK cell depletion was also investigated
on mice survival: data in Fig. 3h show that NK cell-depleted mice
survive significantly less when exposed to EE (37.6±6.9 versus
65.8±15.2 days in EE-undepleted mice, Po0.01, log-rank test).
Similarly to what described for tumour size, the effect of EE is
reduced but maintained on NK cell depletion (SE depleted:
20.2±2 versus EE depleted: 37.6±6.9 days, Po0.01 log-rank
test). No significant difference in survival time is observed in mice
housed in SE, upon NK cell depletion. All together, these data
demonstrate that EE affects tumour size and mice survival
through both NK cell-dependent and NK cell-independent
mechanisms.
We then investigated whether a protective effect could be also
obtained by exogenous IL-15 administration. To this aim, SE
mice were brain-injected with vehicle or IL-15 (50 ngml 1, 3ml)
on day 0 and 10 after glioma transplantation and brains were
analysed at day 17. Results shown in Fig. 4a demonstrate that this
treatment is ineffective in reducing tumour size. In contrast, when
IL-15 is continuously delivered to SE mice with micro-osmotic
pumps from day 10 to 17 after glioma transplantation
(50 ngml 1, 100 ml, 0.5 ml h 1), a significant reduction in
tumour size is observed (Fig. 4b). In these mice, brain infiltration
of NK (that is, NK1.1þ /CD3 /CD45þ ) cells is significantly
increased (Fig. 4c). Interestingly, IL-15 infusion with micro-
osmotic pumps also strongly increases the total number of
activated CD69þ cells (Fig. 4d). When IL-15 is infused in the
brain of NK cell-depleted mice, no significant reduction in
tumour volume is observed, demonstrating that NK cells are
necessary for the antitumour activity of IL-15 (Fig. 4b).
BDNF reduces tumour size and M/M/ infiltration. To identify
the NK cell-independent component of the antitumour activity of
EE, we next investigated the potential role played by BDNF on
glioma growth: to this aim, SE mice were infused with BDNF
(100 ngml 1, 3 ml) or vehicle, 48 h before and during glioma
transplantation and their brains were analysed 17 days later.
Results shown in Fig. 5a demonstrate that this treatment sig-
nificantly reduces tumour volume. Similar results are obtained
when BDNF (or vehicle) is delivered 10 days after glioma
transplantation into the brain of SE mice with micro-osmotic
pumps, for 7 days (100 ngml 1, 100 ml, 0.5 ml h 1). Figure 5b
shows a significant reduction in tumour size in the presence of
BDNF, demonstrating an antitumour effect similar to EE. In the
brain of mice where BDNF was delivered with micro-osmotic
pumps, we also observe a significant reduction of CD68þ cells
(Fig. 5c), indicative of a reduced phagocytic activity of M/Mf.
Interestingly, under these conditions, also the total number of
F4/80þ cells is reduced (Fig. 5d), demonstrating a BDNF-
dependent reduction in M/Mf infiltration of the tumour mass.
All CD68þ cells are M/Mf, as verified by CD68/F4/80 co-
staining (Fig. 5e).
We then tested, in vitro, the effect of BDNF on microglia
functions. Data shown in Fig. 5f,g indicate that BDNF
is ineffective in directly modulating either phagocytic or
chemotactic activity of the microglia. However, BDNF hampers
the increase in phagocytic (Fig. 5f) and chemotactic (Fig. 5g)
activities induced on the microglia by co-culturing with glioma
cells (Fig. 5f,g). All together, these data suggest that BDNF
induces the release of soluble factors by the glioma, acting on
microglia to modulate phagocytosis and chemotaxis.
To further investigate the direct effects of BDNF on glioma, we
analysed the expression of TrkB receptors on GL261 cells using
RT–PCR and western blot analyses. Data shown in Fig. 6a
demonstrate that GL261 cells do not express the full-length form
of TrkB (TrkB.FL) but do express the truncated forms TrkB.T1
and TrkB.T2, both as mRNA (left) and protein (right). The
TrkB.T1 receptor signals to Rho protein dissociation inhibitor
(RhoGDI) that, on BDNF stimulation, detaches from TrkB.T1
and binds to the small G protein RhoA, leading to its inhibition10
(see scheme in Fig. 6b). Data shown in Fig. 6c show that the
BDNF treatment of GL261 cells reduces the basal activation state
of RhoA and completely abolishes epidermal growth factor
(EGF)-induced RhoA activation, as evaluated by a Rhotekin-GST
pull-down assay. Other signalling components activated by EGF,
including FAK and ERK1/2, are inhibited by BDNF co-treatment
(Supplementary Fig. 5a). Functional analysis of cell migration
correlates with BDNF signalling: Fig. 6d shows that GL261 cells
are not attracted by BDNF but migrate towards EGF and,
Table 2 | Expression of selected genes in CD11bþ and CD11b cells isolated from contra- and ipsilateral hemispheres of
glioma-bearing mice housed in SE or EE.
CD11bþ CD11b
SE EE SE EE
C I C I C I C I
bdnf 1.00±0.01 0.80±0.06 2.06±0.20** 2.18±0.26* 1.00±0.01 0.91±0.10 1.86±0.16** 1.80±0.06**
il-15 1.00±0.01 1.20±0.13 2.15±0.41* 2.14±0.40* 1.00±0.02 1.06±0.02 1.07±0.02 0.76±0.10
EE, enriched environment; RT–PCR, real-time–PCR; SE, standard environment.
Results of RT–PCR analysis are shown as fold increases (versus C) of mice housed in SE (n¼ 3–4 Student’s t-test; *Po0.05; **Po0.01).
Table 1 | Expression of selected genes in contra- (C) and
ipsilateral (I) hemispheres of glioma-bearing mice housed in
SE or EE.
SE EE
C I C I
bdnf 1.00±0.01 0.75±0.15 1.96±0.30* 2.24±0.29*
il-15 1.00±0.05 0.83±0.07 1.44±0.13* 1.63±0.06*
ccl2 1.00±0.01 50.55±10* 0.87±0.10 9.04±0.72*
cxcl10 1.00±0.04 5.01±0.36** 0.06±0.01* 1.62±0.16*
il-6 1.00±0.01 3.06±0.01* 1.28±0.16 1.13±0.05*
EE, enriched environment; RT–PCR, real-time–PCR; SE, standard environment.
Results of RT–PCR analysis are shown as fold increases versus C of mice housed in SE for each
condition (n¼4 Student’s t-test; *Po0.05, **Po0.01).
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similarly to the effects on signalling, EGF-induced GL261
migration is completely abolished by BDNF co-treatment.
BDNF has no direct effect on the GL261 cell proliferation
rate and, at variance with data on migration and signalling,
the proliferative activity of EGF is not hampered by BDNF
co-treatment (Supplementary Fig. 5b).
Discussion
In this paper we report for the first time that housing in
EE negatively modulates the growth of mouse and human
intracranial glioma and significantly prolongs mice survival. We
demonstrate that the reduction in glioma size in EE-housed mice
is mediated by an increase in brain IL-15, which favours NK cell
accumulation and antitumour function, and BDNF, which
suppresses M/Mf infiltration and activity, and directly affects
tumour cell migration (see Fig. 7).
Housing in EE is known to modify the brain microenviron-
ment, with beneficial effects on cognitive processes, increase in
neural plasticity and direct influence on neurogenesis, dendritic
spine density and synaptic protein synthesis9,11. Enriched social,
sensory and physical activities are reported to partially prevent
the onset and to reduce the devastating impact of several
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Figure 3 | EE increases NK cell infiltration in the tumour area. (a) CD45þ cells increased in the tumour area of EE-housed mice (n¼4; *Po0.05
Student’s t-test). Representative immunofluorescence is shown on the right, at low (4, top, scale bar 1 mm) and high ( 20, bottom, scale bar 0.1 mm
also for b and c) magnification. (b) CD69þ cells increased in the tumour area of EE-housed mice (n¼4; **Po0.01 Student’s t-test). Representative
immunofluorescence is shown on the right. (c) Analysis of NK1.1 cell infiltration in tumour, expressed as % NK1.1þ cells in the tumour area (±s.e.m.;
*Po0.05 Student’s t-test; n¼ 3–4 mice per condition). Representative immunofluorescence of NK1.1þ cells (green) 17 days after glioma-cell
transplantation in mice housed in SE or EE are shown on the right. (d) CD3/NK1.1þ cells increased in the brain hemisphere injected with glioma on
housing in EE (n¼ 6; *Po0.05 Student’s t-test). Representative FACS analysis of CD3/NK1.1þ cells is shown on the right. (e) Percentage of CD69þ cells
in the CD3/NK1.1þ cell population obtained from the brain of SE or EE mice (n¼6; *Po0.05, Student’s t-test). Representative FACS analyses are shown
below. (f) Mean fluorescence intensity (MFI) of CD69 staining in CD3/NK1.1þ cell population obtained from the brain of SE or EE mice (n¼ 6; *Po0.05,
Student’s t-test). (g) Analysis of tumour volume (expressed as mm3±s.e.m.) in vehicle and NK1.1 Ab-treated mice, housed in SE or EE; n¼ 5; *Po0.05,
two-way ANOVA). (h) Kaplan–Meier curve of glioma-transplanted mice exposed to SE or EE on NK1.1 Ab treatment; n¼ 5; log-rank test **Po0.01.
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neurodegenerative diseases in animal models and in humans12,13,
a phenomenon often referred to as brain cognitive reserve14,15.
The progression of malignant glioma is directly related to its
capability to produce soluble mediators causing neuron killing,
degradation of extracellular matrix and recruitment of local and
peripheral cells, all events contributing to tumour expansion. For
all these reasons, we wondered whether EE could interfere with
the ability of glioma to create a microenvironment favourable to
its expansion. Our results show that housing in EE has
antitumour activity, reducing glioma growth in the brain, as
assessed by classic staining methods and with the brain-clearing
technique16 by using RFP-tagged GL261 cells. The inhibitory
effect of EE is already evident at 11 days after tumour
transplantation, persists until day 17 and parallels the reduction
of cell proliferation (BrdU staining) in the tumour mass. Likely as
a direct consequence of the reduced tumour expansion, housing
in EE significantly prolongs the survival time of glioma-bearing
mice and, intriguingly, also reduces the incidence of tumour
development on glioma transplantation. The effect of EE on
tumour size is not limited to a single cell line, being also obtained
with the human U87MG xenografted in severe combined
immunodeficient (SCID) mice and with a purified CD133þ
GL261 cell population.
The effect of experience in EE on tumour growth was
investigated in a syngeneic murine model of mammary
carcinoma, where EE reduced tumour growth, at least in the
initial phase5. On EE housing, mice with subcutaneous implanted
melanoma or colon cancer had reduced tumour development and
progression, with mechanisms involving hypothalamic BDNF
and sympathetic modulation4. However, these results were not
successfully reproduced in a different laboratory, encouraging
further research with rigorous control of possible confounding
variables7.
We report that the EE-induced reduction in tumour
size is not dependent on the age of the animals at the
beginning of the enrichment period, since it is similarly
observed when the EE started at three (weaning) or eight
(adult) weeks of age. This is in line with other studies showing
that the effect of enrichment is not clearly correlated with
the age at the onset of differential housing conditions17,
at variance with environmental (principally sensory)
deprivation, where specific critical periods have been
identified18. On the other hand, we demonstrate that the length
of EE exposure is critically important for the efficacy of
antitumour activity, suggesting a sort of ‘dose dependency’ of
EE on tumour.
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Figure 4 | IL-15 administration impairs glioma growth and increases NK cell infiltration. (a) Effects on tumour volume of IL-15 or vehicle infusion
into the striatal region of the glioma-injected hemisphere in SE mice, administrated as described in the scheme on top. Brains were analysed 17 days after
glioma transplantation. Graph bars illustrate the mean tumour volume (±s.e.m.; n¼4 mice per condition). (b) Effects of intrastriatal infusion of vehicle
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We demonstrated that EE mice, in the presence of glioma, have
increased mRNA levels of cerebral IL-15, expressed by CD11bþ
cells. Previous evidence demonstrated that short (3min) bouts of
physical exercise increased the IL-15 plasma level in humans19,
suggesting that physical exercise modulates the expression of
genes involved in the regulation of NK cell maturation,
proliferation and activation. However, motor activity is only
one of the aspects potentiated in EE and it is not known whether
more prolonged exercise, similar to that offered to mice in our
experimental protocol, is sufficient to increase cerebral IL-15 in
glioma-bearing mice. Interestingly, we never detect increase of
IL-15 in EE mice in the absence of glioma, suggesting the
requirement of at least two different initiating signals, one from
glioma-conditioned microenvironment and one from factor(s)
produced in the brain on EE housing.
An attractive hypothesis would be that factors in the brain of
EE mice inhibit the acquisition of a pro-tumour phenotype by
CD11bþ M/Mf, thus enhancing their capacity to produce IL-15
in response to tumour cells. In this regard, tumour-infiltrating
M/Mf have lower CD68 expression in EE mice as compared to
SE mice, suggestive of changes in their phenotype, and this is
accompanied by reduced glioma cell proliferation and invasion
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into surrounding parenchyma, and reduced astrogliosis. Since
CD68 is a classic marker of the anti-inflammatory M2-like
phenotype20, our results would suggest a possible EE-mediated
phenotype switch towards a pro-inflammatory, antitumour
M1-like phenotype of infiltrating M/Mf, thus supporting the
protective effects. Interestingly, a recent study demonstrated that
infusion of NK cells with an Ab against NG2/CSPG4 converted
the anti-inflammatory microenvironment of glioblastoma into a
pro-inflammatory one, dominated by M1-like M/Mf21.
We demonstrate that IL-15 expression in the tumour-bearing
brains of EE mice is associated with in situ accumulation of
activated CD45þ /CD69þ leukocytes, and specifically of NK
cells, that are markedly increased in comparison with SE mice.
NK cells play important role in the beneficial effect of EE, since
their depletion strongly reduces the effect of the housing
condition, both in term of tumour size and survival time. These
positive effects are compatible with increased NK cell effector
functions against glioma cells, since NK cells isolated from the
brain of glioma-bearing EE mice are both granzyme B- and
IFN-g-positive. A similar stimulating effect of EE on NK cell
activity and its potential application in tumour immunotherapy
has been proposed for B-cell lymphoma6,8. It remains to be
understood whether, in our experimental model, the reduced
tumour cell proliferation observed in EE-housed mice (as BrdU
staining)is only because of immune-mediated tumour killing.
We show that IL-15 infusion in tumour-bearing SE mice has
the same effect of EE both on tumour size and on NK cell
accumulation in the tumour area, confirming its potential
antiglioma activity22. Importantly, we also demonstrate a direct
link between IL-15 production and NK cell antitumour activity
since IL-15 infusion does not inhibit glioma growth in NK cell-
depleted mice. IL-15 can induce NK cell antiglioma activity
in vivo by promoting their maturation, proliferation and
activation in situ23 or by enhancing NK cell recruitment in the
brain24,25. In addition, recent evidence demonstrated that
activated NK cells, in mouse bearing glioma, communicate with
M/Mf to promote the acquisition of a pro-inflammatory,
M1-like, antitumour phenotype21. All together, these data
prompt to consider IL-15 as the possible therapeutic target in
glioma.
In this paper we confirm that, in the brain of EE mice, BDNF
levels increase26–29. In the brain, BDNF can be produced by
different cell types such as neurons30,31 and microglia32, and its
increase on EE has been correlated with effects on synaptic
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plasticity and cognitive functions in mice33. We demonstrate that
the intracerebral administration of BDNF induces reduction of
tumour size and inhibition of M/Mf infiltration and activation
(as CD68 staining). Considering the crucial roles of infiltrating
M/Mf in glioma growth and progression34, we hypothesize that
the effects of BDNF on M/Mf, likely induced by cross-talk with
glioma, might underlie the observed reduction in tumour size.
BDNF has direct effects on the glioma, mediating the functional
effects observed on M/Mf but also reducing the chemotactic
activity of tumour cells through activation of TrkB.T1 receptor
and inhibition of RhoA signalling, as previously shown35.
Evidence of neurotrophin receptor signalling in glioma
progression is debated: correlative data demonstrate a pro-
migratory activity of p75NTR (ref. 36), while more recent studies
focused on the growth-promoting activity of p75NTR signalling
in glioma stem cells37–39. Our data point to an unambiguous
inhibitory effect on glioma growth by BDNF signalling.
We observe that other cytokines and chemokines, known to be
involved in glioma biology, are modulated in the brain of
EE-housed mice, such as IL-6, CCL2 and CXCL10 (ref. 34). These
cytokines strongly increase in the glioma-bearing hemisphere of
SE mice, and are potently reduced by EE where tumour mass is
reduced. However, at the moment, we cannot conclude whether
the modulation of expression of these cytokines is the cause or the
consequence of tumour volume reduction on EE exposure
and whether their reduction affects the quality of leukocyte
recruitment towards glioma.
In conclusion, confirming the knowledge that the brain milieu
is modulated by environmental stimuli, we now give novel
evidence that prolonged sensory, social and physical experiences
provide the brain with protective inputs that reduce the
probability to develop and favour glioma growth, consistently
increasing the survival time of glioma-bearing mice. This
environment–brain–tumour connection appears to be mediated
by IL-15 and BDNF, cytokines whose level increases in the brain
of EE-housed mice. While IL-15 produced by CD11bþ cells
modulates NK cell infiltration and antitumour activity, BDNF
reduces M/Mf infiltration and the invasion of cerebral
parenchyma by glioma cells through Trkb.T1, both contributing
to limit glioma expansion. These data open new perspectives for
glioma treatment and reinforce the holistic idea that lifestyles,
directly having an impact on the brain microenvironment, reduce
the progression and help to prevent several brain diseases, among
which are tumours.
Methods
Materials. Transwell inserts are from BD Labware (Franklin Lakes, NJ); F4/80,
Trkb (H-181), FAK (A-17) FAK (Tyr397) Abs are from Santa Cruz Biotechnology
(Santa Cruz, CA); GFAP, BrdU Abs are from Novus Biological (Littleton,
CO, USA); CD68 Ab are from AbD Serotec (Oxford, UK); phospho ERK1/2
(Thr202/Tyr204), ERK2 Abs, PCR reactions are from New England Biolabs Inc.
(Hertfordshire, UK); secondary Abs are from DAKO (Milan, Italy); culture media,
B27, fetal bovine serum (FBS), goat serum, penicillin G, streptomycin, glutamine,
Napyruvate, recombinant hEGF, red fluorescent FluoSpheres (1 mm diameter),
Thermo Script RT–PCR System, Hoechst 33342 are from GIBCO Invitrogen
(Carlsbad, CA, USA); BDNF is from Immunological Sciences (Rome, Italy);
BDNF EMAXImmunoAssay System is from Promega (Milan, Italy); BrdU, LPS
(lypopolisaccharides from Escherichia Coli 0111B4), haematoxylin, eosin, Percoll,
tetraHydroFuran, anhydrous (THF), dichloromethane, DiBenzylEther 98% are
from Sigma-Aldrich (Milan, Italy); microbeads CD11bþ are from Miltenyi Biotec
(Bologna, Italy); RNeasy Mini Kit is from Qiagen (Hilden, Germany); RhoA
activation Assay Kit are from Millipore (Merk Millipore, Billerica, MA); CD45,
CD69, CD133, NK1.1 Abs, IL-15 are from eBioscience Inc, (San Diego CA); rat
anti-mouse CD16/CD32 Ab is from BD Pharmingen (Milan Italy); osmotic pump
(Alzet model 1007D, 100 ml; 0.5 ml h 1), cannula (Azlet brain infusion kit 3) are
from Charles River, Italy.
Mice and cell lines. All the experiments were approved by the Italian Ministry of
Health in accordance with the guidelines on the ethical use of animals from the
European Community Council Directive of 24 November 1986 (86/609/EEC). We
used C57BL/6 mice and CB17/Icr-Prkdcscid/IcrIcoCrI (SCID) mice from Charles
River Laboratories, and heterozygous CX3CR1þ /GFP mice (Jackson Laboratories).
We always used male mice, 3 weeks or 2 months of age.
The GL261 murine glioma cells (provided by Dr Serena Pellegatta, Mario Negri
Institute Milan) and U87MG human glioma cells (ATCC) were cultured in DMEM
supplemented with 20% or 10%, respectively, FBS.
Environmental enrichment. Mice were housed for 5 weeks in EE: 10 mice for cage
(36 cm 54 cm 19 cm), in the presence of an assortment of objects, including
climbing ladders, seesaws, running wheel, balls, plastic and wood objects suspended
from the ceiling, paper, cardboard boxes and nesting material. Toys were changed
every 2 days, and the bedding every week. Control SE mice were in pair, in
standard cages: 30 cm 16 cm 11 cm. Both EE and SE groups received chow and
water ad libitum, on a 12-h light/dark cycle.
Electrophysiological recordings. Mice were anaesthetized with halothane and
killed. Whole brains were immersed in ice-cold artificial cerebrospinal fluid
solution containing (in mM): NaCl 125, KCl 4.4, CaCl2 2.5, MgSO4 1.5, NaHPO4 1,
NaHCO3 26 and glucose 10, oxygenated with 95% O2 and 5% CO2 (pH 7.4).
Transverse hippocampal slices (350-mm thick) were cut with a vibratome (DSK,
Japan), allowed to recover for 2 h and transferred to the interface slice-recording
chamber (BSC1, Scientific System Design, at 30–32 C and superfused at
1.5mlmin 1). A concentric bipolar stimulating electrode was positioned in the
stratum radiatum (0.05Hz) of the Schaffer collateral pathway. Orthodromically
evoked fEPSPs were recorded with artificial cerebrospinal fluid-filled glass micro-
pipette (0.5–1MO) and averaged over 1min (n¼ 3). For LTP experiments, fEPSPs
(35–45min post induction) were normalized to baseline values (0–10min) before
LTP induction (HFS, 1 train, 100Hz, 1 s). fEPSPs were recorded and filtered
(1 kHz) with the Axopatch 200A amplifier (Axon Instruments, CA, USA) and
digitized at 10 kHz with A/D converter (Digidata 1322A, Axon Instruments).
Preparation of CD133þ GL261 cells. Single-cell suspensions from cultured
GL261 were incubated for 10min at 4 C with rat anti-mouse CD16/CD32 Ab
(1:250) and for 30min at 4 C with CD133 Ab (1:75). The CD133þ -GL261 cell
population was isolated using phycoerythrin anti-mouse CD133 Ab using a BD
FACS AriaII (BD Biosciences). The purity of cell population was verified using flow
cytometry (B90%). Sorted CD133þ GL261 cells were maintained in DMEM with
20 ngml 1 fibroblast growth factor-2, 20 ngml 1 EGF and Heparin 10Uml 1,
for 24 h before brain transplantation.
Intracranial injection of glioma cells. After 5 weeks in EE or SE, mice were
anaesthetized with chloralhydrate (400mg kg 1, i.p.) and placed in a stereotaxic
head frame. Animals were injected with 7.5 104 GL261 or CD133þ -GL261 cells,
and 5 104 U87MG cells: a median incision ofB1 cm was made, a burr hole was
drilled in the skull and cells were injected in the right striatum ( 2mm lateral,
þ 1mm anteroposterior from the bregma). Cell suspension in PBS (4 ml) was
injected at 1 ml min 1 and 3mm depth. Mice were then again housed in EE or SE
and analysed after 17 days. The 17-day period was chosen on the basis of tumour
dimension and survival time.
Histopathological evaluation of tumour volume and invasiveness. Seventeen
days after GL261 injection, their brains were isolated and fixed in 4% buffered
formaldehyde for morphological evaluation. Coronal brain sections (20 mm),
prepared using the standard procedures, were stained with haematoxylin and eosin.
A section every 100mm was collected, and the tumour area was evaluated using
Image Tool 3.00. For analysis of tumour invasiveness, glioma cells protruding more
than 150 mm from the main tumour mass were counted in at least 20 fields,
obtained from six slices per mice.
Brain-clearing process. The brains were clarified using the 3Disco method16,
dehydrated at room temperature in successive bathes of 50% THF overnight, 80%
THF for 2 h to 100% THF twice for 1 h. The brains were incubated in 100% Di-
ChloroMethan and then transferred overnight into the clearing medium (100%
DiBenzylEther), changed once before sample observation.
Three-dimensional imaging of cleared brains. Whole cleared brains of adult
mice were imaged using a home-made light-sheet ultramacroscope designed as an
open-source versatile ultramicroscopy solution40. The specimens were placed on
the Z-stage of its optical/sample bench in a cubic glass cuvette filled with the
clearing medium. The cuvette was illuminated sequentially by both sides with a
561-nm laser light sheet of 10mW (LBX-4C, Oxxius, Lannion, France). The images
were taken with a charge-coupled device camera (ORCA AG, Hamamatsu, France)
through a 617/73 filter on a macroscope, equipped with a PlanApo  1/0.25 or
 2/0.5 objective (MVX10, Olympus, France). The image acquisition piloted by the
mManager41 software was synchronized with the z-stage movement (10 or 20 mm
steps) to obtain three-dimensional image stacks of the sample.
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Brain and tumour volume measurements. The three-dimensional images
were analysed using the ImageJ software (http://imagej.nih.gov/ij/, 1997–2012).
Multiplying the surface measurement (after maximal projection of the image stack
and thresholding or outlining the brain or tumour) by the height (number of
slices including the brain or tumour multiplied by the z gap between slices) gave
cylinder-like volume estimations of the brains and the tumours.
Survival analysis. Following cell injection, mice were monitored daily. The end
point was defined by the lack of physical activity or death. Survival was calculated
using the Kaplan–Meier method, and statistical analysis was performed using a log-
rank test.
BrdU injection. Seventeen days after cell injection, BrdU was intraperitoneally
(i.p.) injected (50mg kg 1). Two hours later, mice were killed and their brains
processed for immunostaining.
Immunostaining. Cryostat brain sections (10 mm) were incubated with 3% goat
serum in 0.3% Triton X-100 for 1 h at RT, and overnight at 4 C with specific Abs
in 1% goat serum, 0.1% Triton X-100 at the following dilutions: F4/80 (1:50), CD68
(1:200), CD45 (1:400), CD69 (1:200), NK1.1 (1:200), BrdU (1:200) and GFAP
(1:1,000). Sections were then stained with fluorophore-conjugated secondary Abs
and Hoechst for nuclei visualization. For BrdU staining, sections were incubated
15min in 1N HCl for 25min in 2N HCl and then neutralized in 0.1M borate
buffer. For F4/80 staining, coronal sections were first heated in 20min in citrate
buffer (pH 6.0) at 95–100 C.
Image acquisition and data analysis. Fuorescence images were digitized using a
CoolSNAP camera (Photometrics) coupled to a ECLIPSE Ti-S microscope (Nikon)
and processed using the MetaMorph 7.6.5.0 software (Molecular Device). Slices
were scanned by consecutive fields of vision ( 10) to build a single image
per section. Data were expressed as area occupied by fluorescent cells versus total
tumour area (by converting pixel to mm2). For comparison between different
treatments, at least 12 coronal sections per brain around the point of injection were
analysed.
Isolation of CD11bþ cells and extraction of total RNA. Brains of glioma-bearing
mice were cut into small pieces and single-cell suspension was achieved by enzy-
matic digestion in trypsin (0.25mgml 1), in Hank’s balanced salt solution (HBSS)
and mechanical dissociation using a wide-tipped pipette. Cell suspension was
applied to a 30-mm cell strainer and immediately processed for MACS Micro Bead
separation. The CD11bþ cells were magnetically labelled with CD11b Micro
Beads. The cell suspension was loaded on a MACS Column (Miltenyi Biotec)
placed in the magnetic field of a MACS Separator and a negative fraction was
collected. After removing the magnetic field, CD11bþ cells were eluted as positive
fraction. Vitality and purity of CD11bþ cells were assessed using flow cytometry
(FACS). On sorting the positive and negative fractions, total RNA was isolated with
the RNeasy Mini Kit and processed for RT–PCR. The quality and yield of RNAs
were verified with Ultraspec2000 UV/Visible (Pharmacia Biotech).
RT–PCR. Samples were lysed in Trizol reagent for isolation of RNA. Reverse
transcription reaction was performed in a thermocycler using IScript TM RT
Supermix (Bio-Rad) under the following conditions: incubation, 25 C, 5min;
reverse transcription, 42 C, 30min; inactivation, 85 C, 5min. RT–PCR was
carried out in a I-Cycler IQ Multicolor RT–PCR Detection System using SsoFast
EvaGreen Supermix (Bio-Rad). The PCR protocol consisted of 40 cycles at 95 C,
30 s and at 60 C, 30 s. For quantitative analysis the comparative Threshold Cycle
(Ct) method was used, while normalizing to Ct value of GAPDH in the same
sample. Relative quantification was performed using the 2DDCt method42 and
expressed as fold changes in arbitrary values. Primers are listed in Supplementary
Table 3.
Plasmid construction. The piggy Bac transposon-based vector ePB-BSD-PGK-
tagRFP was built by replacing the TRE promoter of the ePB-BSD-TRE-tagRFP
construct43 with the constitutive human phosphoglycerate kinase (PGK) promoter.
GL261 glioma cell transfection. Twenty-four hours before transfection, 50% of
the GL261 growth medium was replaced with fresh culture medium. For trans-
fection, 100ml of DMEM was mixed with 4 ml of Magnetofection NeuroMag (OZ
Bioscience, France) and 1.6 mg of the ePB-BSD-PGK-tagRFP vector and 0.4 mg of
the piggy Bac transposase encoding plasmid. The mixture was incubated for
15–20min at room temperature, and thereafter distributed dropwise over the
culture. Cells were then placed on a magnetic plate and incubated for 15min at
37 C. Transfection was terminated by substitution of 50% of incubation solution
with the fresh culture medium. Cells were selected for blasticidin resistance
(10 mgml 1).
Measurement of BDNF. After 17 days from glioma transplantation, ipsilateral and
controlateral hemispheres of EE or SE mice were disrupted with homogenizer and
analysed for BDNF content using a sandwich ELISA.
Intrastriatal BDNF and IL-15 infusion. Eight-week-old male C57BL/6 mice were
anaesthetized with chloralhydrate (400mg kg 1, i.p.), placed in a stereotaxic head
frame and injected in the right striatum (1mm anteroposterior, 2mm lateral and
3mm deep, according to the atlas) with a Hamylton syringe. BDNF and IL-15 were
dissolved in PBS and infused at the rate of 1 ml min 1: BDNF (100 ngml 1
per 3 ml) was infused for 48 h before and during glioma transplantation; IL-15
(50 ngml 1 per 3 ml) or vehicle were infused during and 10 days after glioma
transplantation.
BDNF and IL-15 delivery with micro-osmotic pumps. Ten days after glioma
transplantation, mice were anaesthetized and implanted with an osmotic pump in
the right striatum using the stereotaxic apparatus. A cannula was implanted
through the same hole used for glioma transplantation and was sealed with dental
cement before connecting to the pump. The pump was placed into a subcutaneous
pocket in the dorsal region. The pumps were filled up with vehicle (PBS), BDNF
(60 ng ml 1) or IL-15 (30 ng ml 1). Before surgery, the pumps and the tubes were
incubated at 37 C overnight in a sterile saline. The experiment continued for
7 days after the pump implantation. BDNF and IL-15 doses were selected on the
basis of the in vitro experiments.
Leukocyte isolation and FACS analysis. Seventeen days after the glioma trans-
plantation, mice were intracardially perfused with PBS, brain rapidly removed,
hemispheres separated and placed into 5ml of ice-cold PBS containing 0.2% bovine
serum albumin, 0.01M EDTA and 1mgml 1 deoxyribonuclease I. The hemi-
spheres were disrupted in a glass homogenizer and passed through a 70-mm nylon
cell strainer. The suspension was centrifuged at 400g for 10min at room tem-
perature; the pellet was resuspended in 4ml of 30% Percoll and overlaid on the top
of a gradient containing 3.5ml of 37% and 3.5ml of 70% Percoll solution. Percoll
was prepared by diluting in HBSS. The gradient was centrifuged at 900g for 20min
at room temperature; cells were collected from the 37 to 70% interface (B3ml) and
washed once with HBSS containing 10% FBS. Blood samples were collected into
heparin-containing tubes by tail vein puncture. After removal of contaminating
erythrocytes, cells were counted, and 30–50 ml of whole blood cells were washed
and resuspended in staining buffer. Cells were then blocked by incubation in ice
with anti-CD16/CD32 (24G2) to prevent nonspecific and Fc-mediated binding.
After 10min, a mixture of the appropriate antibodies was added. Cells were further
incubated on ice for 30min, washed and analysed using a FACSCanto II (BD
Biosciences). Data were elaborated using the FlowJo Version 7.6 software
(Tree Star).
NK1.1þ cell depletion. Depletion was performed using a blocking Ab against
NK1.1, which recognizes an epitope of the NKR1Pc-activating receptor (PK136).
C57BL/6 mice (n¼ 5 per group, EE or SE) were i.p. injected with 200mg (in 100 ml)
of anti-NK1.1 Ab 2 days before, during and 2 and 7 days after glioma transplan-
tation. Seven and seventeen days after glioma surgery, NK cell depletion from the
blood sample was monitored with FACS. Tumour size were measured on day 17.
For survival analysis, NK1.1 Ab injection was repeated once a week until the end
point.
Microglia cultures. Microglia cultures were obtained from mixed glia cultures
derived from the cerebral cortices of postnatal day 0–1 (p0–p1) C57BL/6 mice.
Cortices were chopped and digested in 15Uml 1 papain for 20min at 37 C.
Cells (5 105 cells cm 2) were plated on flasks coated with poly-L-lysine
(100mgml 1) in DMEM supplemented with 10% FBS, 100Uml 1 penicillin and
0.1mgml 1 streptomycin. After 7–9 days, cells were shaken for 2 h at 37 C to
detach and collect microglial cells. These procedures gave almost pure microglial
cell populations.
Proliferation assay in vitro. GL261, plated at a density of 13 104 cm 2, were
treated with BDNF and/or EGF (both at 100 ngml 1) for 24 or 48 h. Cell number
was measured treating cells with detergent containing buffer (0.05% ethyl
hexadecyldimethylammonium bromide, 0.028% acetic acid, 0.05% Triton X-100,
0.3mM NaCl, 0.2mM MgCl2 in PBS pH 7.4) and counting them in a hemacyt-
ometer as described44. In all figures, results are expressed as % of cell proliferation,
taking as 100% the untreated cells in control conditions.
Precipitation assay. For RhoA pull-down assay, 24 h before stimulation, GL261
were seeded (3 106 cells) with 2.5% FBS, and 2 h before treatment, starved in
DMEM. Subsequently, GL261 were exposed for 5min to BDNF (100 ngml 1)
and/or EGF (100 ngml 1). Afterwards, cells were lysed in buffer containing
50mM Tris/HCl, 150mM NaCl, 1% Triton X-100, 0.15% Na deoxycholate, 0.1%
SDS, 50mM Napyruvate 100mM NaF, 1mM EDTA, 1mM EGTA, 10mM MgCl2,
1mM phenylmethyl sulphonyl fluoride, 10 mgml 1 leupeptin and 20mgml 1
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aprotinin, Rhotekin beads (Millipore 23 ml) were added to the lysates and incubated
at 4 C for 3 h. The beads were then washed with the lysis buffer and the result
pellets were mixed with 2 ml dithiothreitol and 25 ml SDS sample buffer, boiled
5min and analysed using western blot analysis.
Western blot. For protein extraction, GL261 were stimulated as previously
described. The same amount of proteins (20 or 50 mg per sample) was loaded on
SDS polyacrylamide gel and electrophoretically transferred to a nitrocellulose
paper. Blots were incubated with specific primary and horseradish peroxidase-
conjugated secondary Abs, and immunoreactivity detected by enhanced chemilu-
minescence. Densitometric analysis was carried out with Chemi-Doc (Bio-Rad).
Images have been cropped for presentation and full-size images are shown in
Supplementary Fig. 6
Phagocytosis. Microglial cells were co-cultured with GL261 as described, in the
presence or in the absence of BDNF (100 ngml 1) for additional 24 h. LPS
(500 ngml 1) was used as the positive control. Red fluorescent FluoSpheres
(0.05% or 1.8 107 spheresml 1) were added for 1 h in 0.1% BSA, and nuclei
were stained with Hoechst. Cells were deeply washed and fixed in 4% paraf-
ormaldehyde for 15min. Phagocytizing cells (scoring as positive only cells with at
least three FluoSpheres to avoid possible false-positives because of sphere adhesion
to the cell surface) were counted in at least 20 random fields (594 nm, Axioscope2;
Carl Zeiss, Oberkochen, Germany).
Boyden chamber chemotaxis assays. Glioma cells were preincubated in the
chemotaxis medium (DMEM without glutamine, 100 IUml 1 penicillin G,
100mgml 1 streptomycin, 0.1% BSA and 25mM HEPES, pH 7.4) supplemented
with AraC 5 mm, for 15min, and plated (4 104 cells) on poly-L-lysine-coated
transwells (8 mm pore size) in this same medium. The lower chamber contained
BDNF (100 ngml 1), EGF (100 ngml 1) or vehicle. After 18 h at 37 C, cells were
treated with ice-cold 10% trichloroacetic acid, cells adhering to the lower side of the
filter were stained (50% isopropanol, 1% formic acid and 0.5% (wt/vol) brilliant
blue R250) and counted (20 fields,  40 objective). For microglia (3 104 cells),
the medium alone or conditioned 24 h by GL261 cells in presence or absence of
BDNF (100 ngml 1) was used as chemoattractant (3 h).
General criteria adopted for the experiments. For each experiment, the sample
size (n) was chosen considering the following relation: nZ2sigma (Zalpha/D)2,
where sigma is substituted by an estimate of variance (s2); alpha is at 0.05 (and
Zalpha¼  2) and D is the difference among treatments. Criteria of animal
exclusion/inclusion were pre-established; animals considered for the analysis were
selected for age. From some analyses we excluded mice that after glioma trans-
plantation did not develop cerebral tumour. At weaning, pups from different
colonies were mixed together and mice were randomly allocated to SE or EE. The
investigators performing the different analyses always received the samples from a
third laboratory member, who was not involved in that specific experiment, to
ensure blinding to the group allocation.
Statistical data analysis. Data shown are the mean±s.e.m. Where appropriate,
Student’s t-test or ANOVA was used, as detailed. Statistical analyses were con-
ducted the using Sigma Plot 11.0 software.
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